Successful progressive challenge after a cutaneous reaction to imatinib mesylate (gleevec): A case report and review of the literature

Miguel Park, Gerald W. Volcheck, Juan C. Guarderas

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The use of imatinib mesylate (Gleevec), a selective tyrosine kinase inhibitor, has become the new gold standard for the treatment of chronic myeloid leukemia. Unfortunately, the medication has been commonly associated with mild to severe cutaneous reactions, which has limited its use for some patients. We describe a case of a successful progressive challenge of a patient with a drug-induced exanthemfrom imatinib mesylate and a review of the literature.

Original languageEnglish (US)
Pages (from-to)345-347
Number of pages3
JournalAllergy and Asthma Proceedings
Volume25
Issue number5
StatePublished - Sep 2004

Fingerprint

Skin
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Pharmaceutical Preparations
Imatinib Mesylate
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Successful progressive challenge after a cutaneous reaction to imatinib mesylate (gleevec) : A case report and review of the literature. / Park, Miguel; Volcheck, Gerald W.; Guarderas, Juan C.

In: Allergy and Asthma Proceedings, Vol. 25, No. 5, 09.2004, p. 345-347.

Research output: Contribution to journalArticle

@article{a7bd3cd27b5047c09f67443e537df9f6,
title = "Successful progressive challenge after a cutaneous reaction to imatinib mesylate (gleevec): A case report and review of the literature",
abstract = "The use of imatinib mesylate (Gleevec), a selective tyrosine kinase inhibitor, has become the new gold standard for the treatment of chronic myeloid leukemia. Unfortunately, the medication has been commonly associated with mild to severe cutaneous reactions, which has limited its use for some patients. We describe a case of a successful progressive challenge of a patient with a drug-induced exanthemfrom imatinib mesylate and a review of the literature.",
author = "Miguel Park and Volcheck, {Gerald W.} and Guarderas, {Juan C.}",
year = "2004",
month = "9",
language = "English (US)",
volume = "25",
pages = "345--347",
journal = "Allergy and Asthma Proceedings",
issn = "1088-5412",
publisher = "OceanSide Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Successful progressive challenge after a cutaneous reaction to imatinib mesylate (gleevec)

T2 - A case report and review of the literature

AU - Park, Miguel

AU - Volcheck, Gerald W.

AU - Guarderas, Juan C.

PY - 2004/9

Y1 - 2004/9

N2 - The use of imatinib mesylate (Gleevec), a selective tyrosine kinase inhibitor, has become the new gold standard for the treatment of chronic myeloid leukemia. Unfortunately, the medication has been commonly associated with mild to severe cutaneous reactions, which has limited its use for some patients. We describe a case of a successful progressive challenge of a patient with a drug-induced exanthemfrom imatinib mesylate and a review of the literature.

AB - The use of imatinib mesylate (Gleevec), a selective tyrosine kinase inhibitor, has become the new gold standard for the treatment of chronic myeloid leukemia. Unfortunately, the medication has been commonly associated with mild to severe cutaneous reactions, which has limited its use for some patients. We describe a case of a successful progressive challenge of a patient with a drug-induced exanthemfrom imatinib mesylate and a review of the literature.

UR - http://www.scopus.com/inward/record.url?scp=8844246390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8844246390&partnerID=8YFLogxK

M3 - Article

C2 - 15603208

AN - SCOPUS:8844246390

VL - 25

SP - 345

EP - 347

JO - Allergy and Asthma Proceedings

JF - Allergy and Asthma Proceedings

SN - 1088-5412

IS - 5

ER -